Published in Neurobiol Dis on April 29, 2011
Cell biology of spinocerebellar ataxia. J Cell Biol (2012) 1.19
Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum (2014) 1.03
Consensus paper: management of degenerative cerebellar disorders. Cerebellum (2014) 0.95
Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94
Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23. Nat Commun (2014) 0.90
Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis (2013) 0.85
A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. Nat Genet (2015) 0.84
Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics (2013) 0.81
Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics. Orphanet J Rare Dis (2013) 0.80
Antisense gene silencing: therapy for neurodegenerative disorders? Genes (Basel) (2013) 0.75
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Identification of tissue-specific microRNAs from mouse. Curr Biol (2002) 34.55
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res (2003) 12.81
Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res (2009) 10.08
The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell (2007) 7.99
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells (2005) 6.72
miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci (2009) 5.27
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet (1997) 4.12
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res (2010) 1.99
Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA (2008) 1.92
Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat Neurosci (1999) 1.90
SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells. Nucleic Acids Res (2009) 1.88
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol (2009) 1.59
CaV2.1 channelopathies. Pflugers Arch (2010) 1.58
Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One (2008) 1.34
Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc Natl Acad Sci U S A (2008) 1.34
Allele-specific RNA interference for neurological disease. Gene Ther (2006) 1.32
C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum Mol Genet (2006) 1.24
Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J (2001) 1.21
Alternative splicing as a molecular switch for Ca2+/calmodulin-dependent facilitation of P/Q-type Ca2+ channels. J Neurosci (2004) 1.10
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09
The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci (2000) 1.04
Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci (2006) 1.02
The carboxy-terminal fragment of alpha(1A) calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. Acta Neuropathol (2009) 0.95
Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci Lett (2003) 0.94
Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics (2007) 0.90
Therapeutic gene silencing strategies for polyglutamine disorders. Trends Genet (2009) 0.89
Toxicity and endocytosis of spinocerebellar ataxia type 6 polyglutamine domains: role of myosin IIb. Traffic (2008) 0.88
Alternative splicing generates a smaller assortment of CaV2.1 transcripts in cerebellar Purkinje cells than in the cerebellum. Physiol Genomics (2005) 0.87
Effect of Abeta exposure on the mRNA expression patterns of voltage-sensitive calcium channel alpha 1 subunits (alpha 1A-alpha 1D) in human SK-N-SH neuroblastoma. Neurochem Int (2006) 0.83
Cell-type-specific alternative splicing in spinocerebellar ataxia type 6. Neurosci Lett (2008) 0.82
The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia type 6. Clin Neuropathol (2009) 0.82
Knockdown of Cav2.1 calcium channels is sufficient to induce neurological disorders observed in natural occurring Cacna1a mutants in mice. Biochem Biophys Res Commun (2009) 0.79
Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma. Life Sci (2005) 0.77
siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94
Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63
RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol (2010) 2.30
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem (2008) 2.09
Brain structure in preclinical Huntington's disease. Biol Psychiatry (2005) 2.05
Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet (2010) 1.99
Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell (2005) 1.84
Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol (2012) 1.76
Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci (2004) 1.71
A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain (2003) 1.58
CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci (2005) 1.57
Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 1.53
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A (2002) 1.48
Spinocerebellar ataxias: an update. Curr Opin Neurol (2007) 1.48
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46
Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J (2009) 1.46
Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem (2003) 1.44
Early detection of periodic sharp wave complexes on EEG by independent component analysis in patients with Creutzfeldt-Jakob disease. J Clin Neurophysiol (2008) 1.42
Toward understanding Machado-Joseph disease. Prog Neurobiol (2011) 1.42
Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev (2003) 1.41
Allele-specific all-or-none PCR product diagnostic strategy for Charcot-Marie-Tooth 1A and hereditary neuropathy with liability to pressure palsies. J Chin Med Assoc (2006) 1.39
Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37
Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem (2005) 1.34
In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis (2008) 1.28
Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis (2012) 1.27
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res (2004) 1.27
The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum Mol Genet (2010) 1.21
Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol (2004) 1.20
Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet (2009) 1.18
Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry (2008) 1.17
Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci (2011) 1.17
Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis (2013) 1.15
Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J Biol Chem (2007) 1.14
Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J Biol Chem (2010) 1.12
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
Cognitive decline and aging: the role of concussive and subconcussive impacts. Exerc Sport Sci Rev (2012) 1.11
Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet (2010) 1.11
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09
Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem (2004) 1.08
FUS, TARDBP, and SOD1 mutations in a Taiwanese cohort with familial ALS. Neurobiol Aging (2010) 1.08
Population-specific spectrum of NOTCH3 mutations, MRI features and founder effect of CADASIL in Chinese. J Neurol (2009) 1.06
Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun (2007) 1.06
Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. J Neurosci (2007) 1.06
Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases. J Biol Chem (2008) 1.05
The mutational spectrum in a cohort of Charcot-Marie-Tooth disease type 2 among the Han Chinese in Taiwan. PLoS One (2011) 1.05
The ubiquitin-conjugating enzyme (E2) Ube2w ubiquitinates the N terminus of substrates. J Biol Chem (2013) 1.03
Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann Neurol (2003) 1.00
RNAi medicine for the brain: progresses and challenges. Hum Mol Genet (2011) 1.00
SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. Clin Chim Acta (2009) 1.00
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One (2010) 0.99
Technology insight: therapeutic RNA interference--how far from the neurology clinic? Nat Clin Pract Neurol (2007) 0.99
A novel route for F-box protein-mediated ubiquitination links CHIP to glycoprotein quality control. J Biol Chem (2006) 0.99
Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. J Mol Biol (2004) 0.98
Transient global amnesia: cerebral venous outflow impairment-insight from the abnormal flow patterns of the internal jugular vein. Ultrasound Med Biol (2007) 0.97
Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum Mol Genet (2007) 0.97
The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. Biochemistry (2013) 0.95
Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94
Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94
PRRT2 mutations in paroxysmal kinesigenic dyskinesia with infantile convulsions in a Taiwanese cohort. PLoS One (2012) 0.94
Fractal dimension analysis for quantifying cerebellar morphological change of multiple system atrophy of the cerebellar type (MSA-C). Neuroimage (2009) 0.93
Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol (2012) 0.92
Impairments in cognitive function and brain connectivity in severe asymptomatic carotid stenosis. Stroke (2012) 0.92
Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. Neuroradiology (2010) 0.91
Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther (2013) 0.91
Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One (2010) 0.91
Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol (2012) 0.91
Asian origin for the worldwide-spread mutational event in Machado-Joseph disease. Arch Neurol (2007) 0.90
Physiologic alterations in ataxia: channeling changes into novel therapies. Arch Neurol (2009) 0.90
A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. Neurobiol Aging (2012) 0.90
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: two novel mutations in the NOTCH3 gene in Chinese. J Neurol Sci (2006) 0.89
Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord (2009) 0.88
Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy. PLoS One (2012) 0.88
Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry (2008) 0.88
Early alterations of autophagy in Huntington disease-like mice. Autophagy (2010) 0.87
Multimodal evoked potentials of Kennedy's disease. Can J Neurol Sci (2007) 0.87
Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res (2012) 0.86
Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6 : a voxel-based FDG-positron emission tomography analysis. J Neurol (2007) 0.86
Mutational origin of Machado-Joseph disease in the Australian Aboriginal communities of Groote Eylandt and Yirrkala. Arch Neurol (2012) 0.85
JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis. J Biol Chem (2013) 0.85
Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6. PLoS One (2012) 0.85
RNA interference in neuroscience: progress and challenges. Cell Mol Neurobiol (2005) 0.84
F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing. J Biol Chem (2014) 0.83
Establishment of a novel fluorescence-based method to evaluate chaperone-mediated autophagy in a single neuron. PLoS One (2012) 0.83
Octarepeat changes of prion protein in Parkinson's disease. Parkinsonism Relat Disord (2008) 0.83
Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels. PLoS One (2010) 0.82
Transcriptional changes and developmental abnormalities in a zebrafish model of myotonic dystrophy type 1. Dis Model Mech (2013) 0.82
Common mitochondrial DNA and POLG1 mutations are rare in the Chinese patients with adult-onset ataxia on Taiwan. J Neurol Sci (2007) 0.82
Compromised mitochondrial complex II in models of Machado-Joseph disease. Biochim Biophys Acta (2011) 0.82
Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3. PLoS One (2012) 0.81
Prolonged cortical relay time of long latency reflex and central motor conduction in patients with spinocerebellar ataxia type 6. Clin Neurophysiol (2003) 0.81
Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications. Mov Disord (2004) 0.81
Mutational analysis of the 5' non-coding region of GJB1 in a Taiwanese cohort with Charcot-Marie-Tooth neuropathy. J Neurol Sci (2013) 0.80
Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci (2007) 0.79